OTC Markets

Alternative Reporting Standard: Disclosure Guidelines for the OTCID Basic Market

Federal and state securities laws require issuers to provide *current information* to the public markets. With a view to facilitating compliance with these laws, OTC Markets Group has created these OTCID Disclosure Guidelines ("Guidelines")[1] that set forth the disclosure obligations that make up the "Alternative Reporting Standard" for companies on the OTCID™ Basic Market and Pink Limited Market. Companies that do not make disclosure directly to the SEC (via EDGAR), a banking regulator, or a non-U.S. regulatory authority may provide disclosure under our "Alternative Reporting Standard." We use information provided by companies under these Guidelines and in accordance with the OTCID Rules to determine eligibility for the OTCID Market or Pink Limited Market as applicable.[2]

Current Information

To be eligible for the OTCID Market, Alternative Reporting companies make the information listed below publicly available through OTCIQ.com:

1. **Initial Disclosure Obligations**

Companies must upload the following documents through OTCIQ.com:

- *Annual Report* for the most recently completed fiscal year.
- *All Quarterly Reports* for the current fiscal year.

Annual or Quarterly Reports are composed of:

- ***Disclosure Statements:*** Disclosure information pursuant to these Guidelines for the applicable period. Available as a fillable form beginning on page 4 of these Guidelines.
- ***Financial Statements:*** Qualifying Financial Statements in accordance with the Financial Statement Requirements specified in Item 9 of these Guidelines.

Qualifying Financial Statements include:

- Audit Letter, if audited
- Balance Sheet
- Statement of Income
- Statement of Cash Flows
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Notes to Financial Statements

2. **Ongoing Requirements**

On an ongoing basis, companies must publish reports through OTCIQ.com on the following schedule:

- Quarterly Reports are due within **45 days** of the quarter end
- Annual Reports are due within **90 days** of the fiscal year end
- Management Certifications are due within **45 days** of the Annual Report due date

[1] These Guidelines have been designed to encompass the "current information" requirements under state and federal securities laws, such as Rules 10b-5 and 15c2-11 of the Securities Exchange Act of 1934 ("Exchange Act") as well as Rule 144 of the Securities Act of 1933 ("Securities Act"), and state Blue Sky laws. However, these Guidelines have not been reviewed by the U.S. Securities and Exchange Commission or any state securities regulator. These Guidelines do not constitute legal advice, and OTC Markets Group makes no assurance that compliance with our disclosure requirements will satisfy any legal requirements. These Guidelines may be amended from time to time, in the sole and absolute discretion of OTC Markets Group, with or without notice.

[2] OTC Markets Group may require companies with securities designated as "Caveat Emptor" or other compliance flags to make additional disclosures to qualify for the OTCID Basic Market.

Other OTCID Eligibility Requirements:

To remain on the OTCID Market, companies must continue to meet all other eligibility requirements of the OTCID Rules in addition to the disclosure requirements listed above.

Pink Limited Market

Companies that do not meet the requirements of the OTCID Market set forth above may still qualify for the Pink Limited Market by meeting the following minimum disclosure requirements.

1. **Initial Requirements:**

   - **Annual Financial Statements:** Publish a report that includes Qualifying Annual Financial Statements, as outlined in Item 9, which cover the past 2 completed fiscal years, provided the most recently completed fiscal year is within the past 16 months.

   - **Company Verified Profile:** The Company must verify the Company Profile through OTCIQ.com, including, but not limited to, a complete list of officers, directors, and service providers; outstanding shares; a business description; contact information; and the name of all company insiders. "Company Insiders" shall include the beneficial owner of 10% or more of the outstanding units or shares of any class of any equity security of the issuer.

2. **Ongoing Requirements:** To remain qualified for the Pink Limited Market, companies must:

   - Publish Qualifying Annual Financial Statements, as outlined in Item 9, within 120 days of the fiscal year end. Should a change in fiscal year end occur, no more than 16 months may elapse from the fiscal year end of the prior Annual Financial Statement.

   - Review and verify the information on the Company Profile through OTCIQ.com at least once every 12 months.

Current Reporting of Material Corporate Events

In addition to the disclosure requirements above, all companies on the OTCID or Pink Limited market are expected to promptly release to the public any news or information regarding corporate events that may be material to the issuer and its securities (including adverse information). Persons with knowledge of such events are considered to be in possession of material nonpublic information and may not buy or sell the issuer's securities until or unless such information is made public. If not included in the issuer's previous public disclosure documents, or if the material events occurs after the publication of such disclosure documents, the issuer shall publicly disclose such events by disseminating a news release **within four (4) business days** following their occurrence and posting such news release through an Integrated Newswire or the OTC Disclosure & News Service via OTCIQ.com.[4]

Material corporate events may include:

- Changes to the company's shell status. Please refer to our FAQ on Shell Companies
- Changes in control of issuer
- Departure of directors or principal officers; election of directors; appointment of principal officers
- Entry into or termination of a material definitive agreement or material agreement not made in the ordinary course of business
- Completion of an acquisition or disposition of assets, including but not limited to merger transactions
- Creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of an issuer
- Triggering events that accelerate or increase a direct or contingent financial obligation including any default or acceleration of an obligation or an obligation under an off-balance sheet arrangement
- Costs associated with exit or disposal activities including material write-offs and restructuring; Material impairments
- Unregistered sales of equity securities
- Material modification to rights of security holders
- Changes in issuer's certifying accountant
- Non-reliance on previously issued financial statements or a related audit report or completed interim review
- Change in a company's fiscal year; Amendments to articles of incorporation or bylaws that were not previously disclosed in a proxy statement or other such disclosure statement.
- Amendments to the issuer's code of ethics, or waiver of a provision of the code of ethics
- Any changes to litigation the issuer may be involved in, or any new litigation surrounding the issuer
- Officer, director, or insider transactions in the issuer's securities
- Disclosure of investor relations, marketing, brand awareness, and stock promotion activities which might reasonably be expected to materially affect the market for its securities or otherwise deemed material by the issuer
- A company's bankruptcy or receivership
- Termination or reduction of a business relationship with a customer that constitutes a specified amount of the company's revenues
- Any material limitation, restriction, or prohibition, including the beginning and end of lock-out periods, regarding the company's employee benefits, retirement and stock ownership plan
- Earnings releases
- Other materially different information regarding key financial or operation trends from that set forth in periodic reports
- Other events the issuer determines to be material

[4] "Integrated Newswire" shall mean a newswire service that is integrated with the OTC Disclosure & News Service and is included on OTC Markets Group's list of Integrated Newswires, as published on https://www.otcmarkets.com/corporate-services/ir-tools-services

- **Waypoint Biomedical Holdings, Inc.**
- 9620 Las Vegas Blvd S, STE E4 # 601, Las Vegas, NV 89123-6508
- Phone: (725) 999-0564 / Fax: (702) 745-4122
- www.waypointbiomedicalholdings.com / john@wyph-inc.com

Quarterly Report
For the period ending June, 30th 2026 **(the "Reporting Period")**

Outstanding Shares
The number of shares outstanding of our Common Stock was:

55,602,852 as of 06/30/2026_ *(Current Reporting Period Date or More Recent Date)*

55,602,852 as of 12/31/2025 *(Most Recent Completed Fiscal Year End)*

Shell Status
Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☒ No: ☐

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control
Indicate by check mark whether a Change in Control[5] of the company has occurred during this reporting period:

Yes: ☐ No: ☒

[5] "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Current issuer: John Richer – Date Change July 3rd 2025, Address: 9620 Las Vegas Blvd S, STE E4 # 601, Las Vegas, NV 89123-6508

Predecessor: Rhys Wyndham Warren, 1333 North Buffalo Drive, Suite 210, Las Vegas, NV 89128

Current State and Date of Incorporation or Registration: Nevada, July 2006

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:
Current issuer: John Richer
Predecessor: Rhys Wyndham Warren
Predecessor: Frank Igwealor

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

Predecessor – Dennis Shepherd (CEO 2007) Note=trading temporarily suspended by the SEC pursuant to Section 12(k) of the Securities Exchange Act of 1934 from 9:30AM EST on 3-8-07 through 11:59PM EDT on 3-21-07

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

Current issuer: John Richer

Address of the issuer's principal executive office:

9620 Las Vegas Blvd S, STE E4 # 601, Las Vegas, NV 89123-6508

Address of the issuer's principal place of business:

[X] *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

______

2) Security Information

Transfer Agent

Name: Pacific Stock Transfer Company
Phone: (800) 785-7782
Email: ipstc@pacificstocktransfer.com
Address: 6725 Via Austi Pkwy #300, Las Vegas, NV 89119

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	WYPH	
Exact title and class of securities outstanding:	Common Stock, Special 2020 Series A Preferred Stock	
CUSIP:	946755204	
Par or stated value:	0.001	
Total shares authorized:	100,000,000	as of date: 06/30/2026
Total shares outstanding:	55,602,852	as of date: 06/30/2026
Total number of shareholders of record:	318	as of date: 06/30/2026

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

N/A

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	Special 2020 Series A Preferred Stock	
Par or stated value:	0.001	
Total shares authorized:	100	as of date: June 30th, 2026
Total shares outstanding:	100	as of date: June 30th, 2026
Total number of shareholders of record:	2	as of date: June 30th, 2026

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

N/A

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

   1 vote per share for Common Equity.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

   10 votes per share of Special 2020 Series A Preferred Stock

3. Describe any other material rights of common or preferred stockholders. N/A

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

   N/A

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities ***in the past two completed fiscal years and any subsequent interim period****.*

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☒ Yes: ☐ (If yes, you must complete the table below)

Shares Outstanding Opening Balance: Date 03/31/2026 Common: 55,602,852 Preferred: 95	*Right-click the rows below and select "Insert" to add rows as needed.

Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued ($/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
——	——	——	——	——	——	——	——	——	——
Shares Outstanding on Date of This Report: Ending Balance: Date 03/31/2026 Common: 55,602,852 Preferred: 100									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

N/A

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

[☒] Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance ($)	Outstanding Balance ($) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion[6]	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

[6] The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Total Outstanding Balance: **Total Shares:**

Any additional material details, including footnotes to the table are below:

N/A

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.
Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

No operations

B. List any subsidiaries, parent company, or affiliated companies.

No operations

C. Describe the issuers' principal products or services.

No operations

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

No operations

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or **Entity Name** (Include names of control person(s) if a corporate entity)	**Position/Company Affiliation** (ex: CEO, ≥ 5% beneficial owner)	**City and State** (Include Country if outside U.S.)	**Number of Shares Owned** (List common, preferred, warrants and options separately)	**Class of Shares Owned**	**Percentage of Class of Shares Owned** (undiluted)
John Richer	President	North Bend, OR	1,700,000	Common	3%
John Richer	President	North Bend, OR	95	Preferred	95%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, <u>in the past 10 years</u>:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

<u>No</u>

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

<u>No</u>

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state

securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.
Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name:	Howard & Howard, Inc.
Address 1:	3800 Howard Hughes Pkwy
Address 2:	STE 1000, Las Vegas, NV 89169
Phone:	**D:** 702.667.4857 | **F:** 702.567.1568
Email:	mpettiford@howardandhoward.com

Accountant or Auditor

Name:	Daniel Barakat
Firm:	1800Accountant
Address 1:	260 Madison Ave.

Address 2: Suite 1001, New York, NY 10016.
Phone: 1-800-222-6868.
Email: Daniel <dbarakat@1800accountant.com>

Investor Relations

Name: N/A
Firm: N/A
Address 1: N/A
Address 2: N/A
Phone: N/A
Email: N/A

All other means of Investor Communication:

X (Twitter): N/A
Discord: N/A
LinkedIn N/A
Facebook: N/A
[Other] N/A

Other Service Providers
Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: N/A
Nature of Services: N/A
Address 1: N/A
Address 2: N/A
Phone: N/A
Email: N/A

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **John Richer**
Title: **President & CEO**
Relationship to Issuer: **President & CEO**

B. The following financial statements were prepared in accordance with:

☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Daniel Barakat**

Title: **CPA**
Relationship to Issuer: **CPA**
Describe the qualifications of the person or persons who prepared the financial statements:[7] **CPA**

Provide the following qualifying financial statements:

- o Audit letter, if audited;
- o Balance Sheet;
- o Statement of Income;
- o Statement of Cash Flows;
- o Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- o Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable." Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

[7] The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Waypoint Biomedical Holdings, Inc.

Accountant's Compilation
And Financial Statements

June 30, 2026 and 2025

TABLE OF CONTENTS

DGB Consulting Services LLC
Certified Public Accountants
2502 N Dixie Hwy, Suite 48
Lake Worth Beach, FL 33460

August 11, 2026

To: Management

Waypoint Biomedical Holdings, Inc.
9620 Las Vegas Blvd S, STE E4 #601
Las Vegas, NV 89123-6508

Management is responsible for the accompanying financial statements of Waypoint Biomedical Holdings, Inc. which comprise the balance sheet as of June 30, 2026 and 2025, and the related statement of operations, and cash flows for the periods then ended, in accordance with accounting principles generally accepted in the United States of America. I have performed a compilation engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. I did not audit or review the financial statements nor was I required to perform any procedures to verify the accuracy or completeness of the information provided by management. Accordingly, I do not express an opinion, a conclusion, nor provide any form of assurance on the financial statements.

Daniel Barakat

Daniel Barakat, CPA
Lake Worth Beach, Florida

Waypoint Biomedical Holdings, Inc.
Balance Sheet
As of June 30

	2026	2025
Assets		
Total Assets	$ -	$ -
Liabilities		
Current Liabilities		
Accounts Payable	$ 54,775	$ 14,739
Related Party Payable	$ 1,816	$ 1,816
Total Liabilities	**56,591**	**16,555**
Equity		
Retained Earnings	$ (936,376)	$ (863,812)
Additional Paid-in Capital	$ 833,981	$ 833,981
Capital Stock	$ 55,603	$ 55,603
Net Income	$ (9,799)	$ (42,327)
Total Equity	$ (56,591)	$ (16,555)
Total Liabilities and Equity	$ -	$ -

Waypoint Biomedical Holdings, Inc.

Statement of Operations

	Three Months Ended June 30 2026	Three Months Ended June 30 2025	Six Months Ended June 30 2026	Six Months Ended June 30 2025
Income				
Gross Profit	$ -	$ -	$ -	$ -
Expenses				
Accounting	$ 1,000	$ -	$ 4,300	$ -
Auto Expense	$ 75	$ 265	$ 210	$ 515
Business Consultant	$ -	$ 3,000	$ 1,565	$ 31,000
Dues and Subscriptions	$ -	$ -	$ 1,204	$ -
Office Expenses	$ 278	$ 605	$ 556	$ 680
OTC Markets Fees	$ -	$ -	$ -	$ -
Telephone	$ 156	$ 240	$ 287	$ 375
Transfer Agent Fees	$ 522	$ 6,245	$ 1,029	$ 6,245
Travel	$ -	$ 2,662	$ -	$ 2,662
Utilities	$ 324	$ 375	$ 648	$ 850
Total Expenses	**$ 2,355**	**$ 13,392**	**$ 9,799**	**$ 42,327**
Net Income	**$ (2,355)**	**$ (13,392)**	**$ (9,799)**	**$ (42,327)**

Waypoint Biomedical Holdings, Inc.
Statement of Cash Flows
For the Six Months Ended June 30

	2026	2025
Operating Activities		
Net Income (Loss)	$ (9,799)	$ (42,327)
Adjustments to reconcile Net Income (Loss) to Net Cash provided by Operations:		
Accounts Payable	$ 9,799	$ 14,739
Total Adjustments to reconcile Net Income (Loss) to Net Cash provided by Operations:	$ 9,799	$ 14,739
Net cash provided by (used in) operating activities	**$ -**	**$ (27,588)**
Investing Activities		
Net cash provided by (used in) investing activities	**$ -**	**$ -**
Financing Activities		
Preferred Stock Issuance	$ -	$ 2,588
Common Stock Issuance	$ -	$ 25,000
Net cash provided by (used in) financing activities	**$ -**	**$ 27,588**
Net Cash Change for the Period	$ -	$ -
Cash Balance - Beginning of Year	$ -	$ -
Cash Balance - End of Year	$ -	$ -

Waypoint Biomedical Holdings, Inc.
Statement of Changes in Shareholders' Equity
For the Six Months Ended June 30, 2026

	Preferred Stock	Common Stock		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders' Equity (Deficit)
	# of Shares	# of Shares						
Balance, January 1, 2024	-	30,602,852	$	831,393	$	(863,812)	$	(1,816)
Net income (loss) – 2024	-	-	$	-	$	-	$	-
Balance, December 31, 2024	-	30,602,852	$	831,393	$	(863,812)	$	(1,816)
Issuance of common stock (25,000,000 shares)	-	25,000,000	$	-	$	-	$	25,000
Net income (loss) - (Q1 2025)	-	-	$	-	$	(28,935)	$	(28,935)
Balance, March 31, 2025	-	55,602,852		831,393		(892,747)		(5,751)
Issuance of Series A Preferred Stock (95 shares)	95	-	$	2,588	$	-	$	2,588
Net income (loss) – (Q2 2025)	-	-	$	-	$	(13,392)	$	(13,392)
Balance, June 30, 2025	95	55,602,852		833,981		(906,139)		(16,555)
Net income (loss) – (Q3 - Q4 2025)	-	-	$	-	$	(30,237)	$	(30,237)
Balance, December 31, 2025	95	55,602,852		833,981		(936,376)		(46,792)
Net income (loss) – (Q1 2026)	-	-	$	-	$	(7,444)	$	(7,444)
Balance, March 31, 2026	95	55,602,852		833,981		(943,820)		(54,236)
Net income (loss) – (Q2 2026)	-	-	$	-	$	(2,355)	$	(2,355)
Balance, June 30, 2026	95	55,602,852		833,981		(946,175)		(56,591)

Waypoint Biomedical Holdings, Inc.
June 30, 2026 and 2025
Notes to Financial Statements

Note 1 – Summary of Significant Accounting Policies

Nature of Operations

Waypoint Biomedical Holdings, Inc. (the "Company") is a Nevada corporation whose common stock is quoted on the OTC Markets under the symbol WYPH. During the period ended June 30, 2026, the Company incurred operating expenses in connection with regulatory compliance, corporate maintenance, and efforts to maintain public company status. The Company did not generate revenue during the period.

Basis of Accounting

The Company maintains its books and records on the accrual basis of accounting and the financial statements are prepared in accordance with accounting principles generally accepted in the United States of America and are presented for purposes of OTC Markets disclosure.

Note 2 – Operating Expenses

During the period ended June 30, 2026, the Company incurred operating expenses totaling $2,355, primarily related to professional services, regulatory fees, transfer agent services, travel, and general corporate expenses.

Note 3 – Common Stock

As of June 30, 2026, the Company had 55,602,852 shares of common stock issued and outstanding.

Note 4 – Preferred Stock

As of June 30, 2026, the Company had 95 shares of Special 2020 Series A Preferred Stock issued and outstanding.

Note 5 – Related Party Payable

As of June 30, 2026, the Company had a related party payable of $1,816, unchanged from prior periods. The payable is unsecured, non-interest bearing, and due on demand.

Note 6 – Income Taxes

The Company has incurred net operating losses for tax purposes. Deferred tax assets associated with these losses are fully offset by a valuation allowance. Accordingly, no deferred tax assets or liabilities were recognized.

Note 7 – Subsequent Events

Management evaluated subsequent events through August 11, 2026, the date these financial statements were available to be issued and determined that no events occurred requiring disclosure.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, John Richer, President & CEO, certify that:

1. I have reviewed this Disclosure Statement for Waypoint Biomedical Holdings, Inc;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

06/30/2026

/s/John Richer [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, John Richer, CEO certify that:

1. I have reviewed this Disclosure Statement for Waypoint Biomedical Holdings, Inc;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

06/30/2026 [Date]

/s/John Richer [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")